Funding for this research was provided by:
Innovative Medicines Initiative Joint Undertaking (EMIF grant: 115372)
Received: 10 June 2018
Accepted: 4 September 2018
First Online: 27 September 2018
Ethics approval and consent to participate
: The local medical ethics committee in each centre approved the study. Subjects had already provided written informed consent at the time of inclusion in the cohort for use of data, samples and scans.
: Not applicable.
: The authors declare that they have no competing interests. HZ has served on scientific advisory boards of Eli Lilly and Roche Diagnostics, has received travel support from Teva and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. MFG’s current employer is Teva Pharmaceuticals, Inc., Malvern, PA, USA; his former employer was Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. Any views expressed in this publication represent the personal opinions of the authors and not those of their respective employer. JCR is a full-time employee of GlaxoSmithkline. PM-L reports personal fees from Lilly, Axon, General Electric and Nutricia for advisory boards, and lecturing fees from Lilly, Nutricia, Piramal. RV was principal investigator of the phase 1 and 2 [<sup>18</sup>F]flutemetamol trials. RV’s institution has clinical trial agreements (RV as PI) with AbbVie, Biogen, EliLilly, Merck and Novartis, and consultancy agreements (RV as PI) with Novartis and Cytox Ltd. SL has done consultancy for Eaisi, EIP Pharma, SomaLogic, Merck and Optum Labs.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.